Trial Information

Comparison of the Diagnostic Accuracy of 3D Volume Acquisition MRI With CT in Staging Colonic Cancer

The patient will proceed with their usual colon cancer assessment and treatment, including
colonoscopy with biopsy and histology and preoperative CT chest abdomen and pelvis. In
addition, patients who enroll in the study will have 2 preoperative MRIs of their abdomen
and pelvis performed. One of these will be performed on a 1.5T and the other will be
performed on a 3.0T MRI scanner. We will use 20mg of IM buscopan to reduce bowel mobility
for each scan. A coronal scout scan will be taken to identify the tumour and select the
target volume. IV gadolinium (a contrast agent routinely used in MRI scans to help identify
different tissues) will be administered, and a 3D VIBE scan (T1 weighted) will be performed
of the target volume. The liver will also be imaged at this time to look for liver
metastases. A T2 weighted 3D volume acquisition will then be obtained of the target volume
containing the tumour (and its lymphatic drainage).

The MRI will be independently reported by an expert without knowledge of the results of any
other investigations. The results of the MRI scan will then be made available to the
clinical team. The patient will then proceed as normal with any other investigation which
the clinical team feel is necessary, and be treated as normal for their colon cancer. The
patient will proceed with their surgery as normal, and the specimen removed at the time of
the operation will be examined in the pathology laboratory to determine the exact stage of
the cancer.

The accuracy of CT and MRI in staging colon cancer will then be determined against the
reference standard provided by the histology examination.